Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-15

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related\_conditions/mild-cognitive-impairment. Accessed August 16, 2022). MCI does not substantially interfere with daily activities, although complex functional tasks may be performed less efficiently (Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459. doi:10.1016/j.mayocp.2014.06.019). Approximately 30% of MCI patients have Alzheimer's disease (AD) as a cause of their symptoms (Lopez,OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol. 2007;64(3):416-420.doi:10.1001/archneur.64.3.416)). In contrast, dementia is defined by chronic, acquired loss of two or more cognitive abilities caused by brain disease or injury, often associated with significant interference with the ability to function at work or at usual activities. (Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc. 2014;89(10):1452-1459. doi:10.1016/j.mayocp.2014.06.019). Approximately 60-80% of dementia patients have AD as a cause of their symptoms (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related\_conditions/mild-cognitive-impairment. Accessed August 16, 2022).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099

Alzheimer Disease Mild Cognitive Impairment Dementia

RECRUITING

Brain Imaging in Elderly People and Individuals With Alzheimer's Disease

NCT00001917

Alzheimer's Disease Healthy

COMPLETED

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NCT02966145

Corticobasal Degeneration (CBD) Corticobasal Syndrome (CBS) Cortical-basal Ganglionic Degeneration (CBGD) +3 more

COMPLETED

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971

Mild Cognitive Impairment (MCI) Alzheimer's Disease (AD) Significant Memory Concern (SMC) +2 more

COMPLETED

Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II

NCT02317250

Mild Cognitive Impairment

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Quality Improvement PrecivityAD2(TM) Clinician Survey and Clinical Utility Study (QUIP II) represents a large-scale initiative for the PrecivityAD2 blood test for use by neurologists, geriatricians, and geropsychiatrists (memory care specialists) who see patients aged 55 years and older with signs or symptoms of MCI or dementia.

C₂N Diagnostics, LLC is a CLIA-certified, CAP-accredited diagnostic testing laboratory based in St. Louis, MO. Its new test, the PrecivityAD2 blood test, measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease Mild Cognitive Impairment Dementia Cognitive Decline Cognitive Impairment Memory Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort A

One time clinician survey post-test following the receipt of the PrecivityAD2 blood test result

PrecivityAD2(TM) blood test

Intervention Type OTHER

The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.

Cohort B

Pre-test as well as post-test and close-out survey following the receipt of the PrecivityAD2 blood test result

PrecivityAD2(TM) blood test

Intervention Type OTHER

The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PrecivityAD2(TM) blood test

The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AD2

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Memory care specialists actively practicing in the United States
2. Practice serves individuals with MCI or dementia age \> 55 years
3. Average patient volume \> 25 visits per week (all patients seen across practice)
4. Memory care specialist with access to an online electronic survey

1. Individual with MCI or dementia
2. Age \>= 55 years

Exclusion Criteria

1\) Clinicians who practice in New York

1. Individual requiring test related blood draw within the state of New York
2. Participation does not seem to be in the best interest of the individual, per the ordering clinician

Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No